Cargando…

Changes in Opioid Utilization Following Tumor Necrosis Factor Inhibitor Initiation in Patients with Rheumatoid Arthritis

INTRODUCTION: Pain control is one of the most important aspects of rheumatoid arthritis (RA) management from the patient’s perspective. Newer generations of RA treatment including tumor necrosis factor inhibitor (TNFi) have the potential to alleviate pain and thus reduce opioid utilization. However,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Siyeon, Le, Tham T., Slejko, Julia F., Villalonga-Olives, Ester, Onukwugha, Eberechukwu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858479/ https://www.ncbi.nlm.nih.gov/pubmed/31628617 http://dx.doi.org/10.1007/s40744-019-00175-6

Ejemplares similares

The Economic Burden of Comorbid Obstructive Sleep Apnea Among Patients with Chronic Obstructive Pulmonary Disease
por: Hong, Yoon Duk, et al.
Publicado: (2020)

Utilization of novel systemic therapies for multiple myeloma: A retrospective study of front‐line regimens using the SEER‐Medicare data
por: Goto, Daisuke, et al.
Publicado: (2019)

Economic burden of interstitial lung disease in a commercially insured population with Sjögren syndrome in the United States
por: Lee, Tsung-Ying, et al.
Publicado: (2022)

Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness Analysis
por: Mattingly, T. Joseph, et al.
Publicado: (2019)

Big Data and Its Role in Health Economics and Outcomes Research: A Collection of Perspectives on Data Sources, Measurement, and Analysis
por: Onukwugha, Eberechukwu
Publicado: (2016)

Valuing diversity in value assessment: introducing the PhRMA Foundation Health Disparities Challenge Award
por: Onukwugha, Eberechukwu
Publicado: (2021)

Predictors of Treatment Initiation with Tumor Necrosis Factor-α Inhibitors in Patients with Rheumatoid Arthritis
por: Desai, Rishi J., et al.
Publicado: (2014)

Cost-utility analysis of treatment options after initial tumor necrosis factor inhibitor therapy discontinuation in patients with rheumatoid arthritis
por: Karpes Matusevich, Aliza R, et al.
Publicado: (2021)

Why the Gap in Evaluating the Social Constructs and the Value of Medicines?
por: McRae, Jacquelyn, et al.
Publicado: (2021)

Response to Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis for Function and Pain is Affected by Rheumatoid Factor
por: Aberumand, Babak, et al.
Publicado: (2014)

Biologics Initiation in Rheumatoid Arthritis by Race and Ethnicity: Results From a Randomized Survey Study
por: Simard, Julia F., et al.
Publicado: (2023)

Burden of Co-Infection: A Cost Analysis of Human Immunodeficiency Virus in a Commercially Insured Hepatitis C Virus Population
por: Mattingly, T. Joseph, et al.
Publicado: (2019)

Rheumatoid Arthritis: Refractory to Infliximab, a Tumor Necrosis Factor Inhibitor
por: Solehan, Hana Maizuliana bt, et al.
Publicado: (2011)

Social capital and cost-related medication nonadherence (CRN): A retrospective longitudinal cohort study using the Health and Retirement Study data, 2006–2016
por: Majercak, Kayleigh R., et al.
Publicado: (2020)

Social Capital during the First Wave of the COVID-19 Outbreak: The Case of the Island of Menorca
por: Villalonga-Olives, Ester, et al.
Publicado: (2021)

Cost–utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting
por: Hallinen, Taru A., et al.
Publicado: (2010)

Effect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts Precursors in Rheumatoid Arthritis
por: Perpétuo, Inês P., et al.
Publicado: (2017)

Capturing the patient experience in systemic lupus erythematosus: Are widely used measures fit-for-purpose and adherent to FDA PRO guidance recommendations?
por: Majercak, Kayleigh R., et al.
Publicado: (2022)

Emergent Social Capital during the Coronavirus Pandemic in the United States in Hispanics/Latinos
por: Contreras, Jennifer, et al.
Publicado: (2023)

Pain Reduction in Rheumatoid Arthritis Patients Who Use Opioids: A Post Hoc Analysis of Phase 3 Trials of Baricitinib
por: Pope, Janet E., et al.
Publicado: (2021)

Patient Perception of Cardiovascular Risk in Rheumatoid Arthritis
por: Banerjee, Shubhasree, et al.
Publicado: (2020)

Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis
por: Kavanaugh, Arthur, et al.
Publicado: (2018)

Longitudinal changes in health related quality of life in children with migrant backgrounds
por: Villalonga-Olives, Ester, et al.
Publicado: (2017)

Longitudinal impact of volunteering on the cognitive functioning of older adults: A secondary analysis from the US Health and Retirement Study
por: Villalonga-Olives, Ester, et al.
Publicado: (2023)

Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors
por: Tanaka, Toshio, et al.
Publicado: (2014)

Efficacy predictors of a second tumor necrosis factor inhibitor in the treatment of rheumatoid arthritis
por: Reams, Jennifer, et al.
Publicado: (2020)

Acquired Factor VIII Inhibitor in a Patient of Rheumatoid Arthritis on Tumor Necrosis Factor Inhibitor Therapy
por: Mori, Tomoyo, et al.
Publicado: (2018)

Interference of tumor necrosis factor inhibitor treatments on soluble tumor necrosis factor receptor 2 levels in rheumatoid arthritis
por: Yang, Nicole, et al.
Publicado: (2019)

Development and validation of a questionnaire to measure family social capital
por: Carrillo-Álvarez, Elena, et al.
Publicado: (2019)

Patient-reported outcomes in breast cancer FDA drug labels and review documents
por: Hong, Kyungwan, et al.
Publicado: (2021)

Respiratory events associated with concomitant opioid and sedative use among Medicare beneficiaries with chronic obstructive pulmonary disease
por: Le, Tham Thi, et al.
Publicado: (2020)

Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
por: Kavanaugh, Arthur, et al.
Publicado: (2018)

Influence of tumor necrosis factor α in rheumatoid arthritis
por: Kulp, Werner, et al.
Publicado: (2005)

Predictive factors for effective selection of Interleukin-6 inhibitor and tumor necrosis factor inhibitor in the treatment of rheumatoid arthritis
por: Hayashi, Shinya, et al.
Publicado: (2020)

Drug Survival Rates of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis
por: Kang, Ji-Hyoun, et al.
Publicado: (2014)

Association Between Ischemic Stroke and Tumor Necrosis Factor Inhibitor Therapy in Patients With Rheumatoid Arthritis
por: Low, Audrey S. L., et al.
Publicado: (2016)

Effect of tumor necrosis factor inhibitors on interstitial lung disease in rheumatoid arthritis: angel or demon?
por: Huang, Ying, et al.
Publicado: (2019)

Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis
por: Massey, Jonathan, et al.
Publicado: (2018)

Tumor Necrosis Factor-Alpha Inhibitors and Cardiovascular Risk in Rheumatoid Arthritis: A Systematic Review
por: Nair, Shaalina, et al.
Publicado: (2022)

Changes in Bone Metabolism in Patients with Rheumatoid Arthritis during Tumor Necrosis Factor Inhibitor Therapy
por: Janković, Tanja, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_o5k1ee4tm5p7q2cbenu3jhs0qn